Literature DB >> 25224075

Chemotherapy-induced changes in cardiac capillary permeability measured by fluorescent multiple indicator dilution.

Alicia Fernandez-Fernandez1, Denny A Carvajal, Tingjun Lei, Anthony J McGoron.   

Abstract

Anthracyclines cause severe irreversible cardiac toxicity. The study of changes in cardiac permeability with chemotherapy could enhance the understanding of mechanisms behind cardiac damage, and provide useful information to evaluate anthracycline cardiotoxicity. Thirty-six rats (12 Sprague-Dawley, 12 Wistar, 12 Fischer-344) were randomly assigned to control (n = 21) or doxorubicin (n = 15), and injected i.p. with a cumulative dose of 18 mg/kg doxorubicin in saline (vehicle) or vehicle alone over 12 days. Echocardiography was performed at baseline and on day 11. An isolated heart experiment was done on day 12 to obtain perfused heart pressure values, and to measure cardiac capillary permeability using a Texas Red/sodium fluorescein multiple indicator dilution method. Control animals had significantly lower average permeability-surface-area-products (0.035 ± 0.013 cm(3)/s) than doxorubicin animals (0.066 ± 0.023 cm(3)/s), PSP ± SD, p < 0.001. These permeability changes correlated with significant functional changes. There was a significant decline in cardiac function with a deleterious effect of chemotherapy on fractional shortening (p < 0.001), left ventricular developed pressure (p < 0.001), contractility (p < 0.001), and relaxation (p = 0.02). Based on our results, cardiac capillary permeability changes can be detected after in vivo chemotherapy treatment using our fluorescent multiple indicator dilution technique, and may provide valuable information in evaluating cardiotoxicity of novel drugs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25224075      PMCID: PMC4241122          DOI: 10.1007/s10439-014-1110-9

Source DB:  PubMed          Journal:  Ann Biomed Eng        ISSN: 0090-6964            Impact factor:   3.934


  37 in total

1.  Indicator dilution methods for measuring blood flow, volume, and other properties of biological systems: a brief history and memoir.

Authors:  K Zierler
Journal:  Ann Biomed Eng       Date:  2000-08       Impact factor: 3.934

Review 2.  A systematic approach for establishing humane endpoints.

Authors:  D B Morton
Journal:  ILAR J       Date:  2000

3.  Role of daunorubicinol in daunorubicin-induced cardiotoxicity as evaluated with the model of isolated perfused rat heart.

Authors:  D Platel; S Bonoron-Adèle; J Robert
Journal:  Pharmacol Toxicol       Date:  2001-05

4.  Progressive cardiac dysfunction in adriamycin-induced cardiomyopathy rats.

Authors:  K Teraoka; M Hirano; K Yamaguchi; A Yamashina
Journal:  Eur J Heart Fail       Date:  2000-12       Impact factor: 15.534

5.  Preclinical evaluation of the cardiotoxicity of taxane-anthracycline combinations using the model of isolated perfused rat heart.

Authors:  D Platel; P Pouna; S Bonoron-Adèle; J Robert
Journal:  Toxicol Appl Pharmacol       Date:  2000-03-01       Impact factor: 4.219

6.  Neutral and DEAE dextrans as tracers for assessing lung microvascular barrier permeability and integrity.

Authors:  Jonathan R Sanders; N Adrienne Pou; Robert J Roselli
Journal:  J Appl Physiol (1985)       Date:  2002-07

7.  Use of multiple fluorophores for evaluating microvascular permeability in control rats and rats with sepsis.

Authors:  Ragheb A Assaly; Robert H Habib; Mustafa Azizi; Joseph I Shapiro; J David Dignam
Journal:  Clin Sci (Lond)       Date:  2008-01       Impact factor: 6.124

8.  Baseline echocardiographic values for adult male rats.

Authors:  Linley E Watson; Milan Sheth; Robert F Denyer; David E Dostal
Journal:  J Am Soc Echocardiogr       Date:  2004-02       Impact factor: 5.251

9.  Prominent cardioprotective effects of third generation beta blocker nebivolol against anthracycline-induced cardiotoxicity using the model of isolated perfused rat heart.

Authors:  Filomena de Nigris; Monica Rienzo; Concetta Schiano; Carmela Fiorito; Amelia Casamassimi; Claudio Napoli
Journal:  Eur J Cancer       Date:  2008-01-14       Impact factor: 9.162

Review 10.  Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity.

Authors:  Giorgio Minotti; Pierantonio Menna; Emanuela Salvatorelli; Gaetano Cairo; Luca Gianni
Journal:  Pharmacol Rev       Date:  2004-06       Impact factor: 25.468

View more
  3 in total

1.  What is considered cardiotoxicity of anthracyclines in animal studies.

Authors:  Nikolaos Georgiadis; Konstantinos Tsarouhas; Ramin Rezaee; Haritini Nepka; George E N Kass; Jean-Lou C M Dorne; Dimitrios Stagkos; Konstantinos Toutouzas; Demetrios A Spandidos; Dimitrios Kouretas; Christina Tsitsimpikou
Journal:  Oncol Rep       Date:  2020-07-14       Impact factor: 3.906

Review 2.  Noncoding RNAs in doxorubicin-induced cardiotoxicity and their potential as biomarkers and therapeutic targets.

Authors:  Hong-Ge Fa; Wen-Guang Chang; Xue-Juan Zhang; Dan-Dan Xiao; Jian-Xun Wang
Journal:  Acta Pharmacol Sin       Date:  2020-07-21       Impact factor: 6.150

3.  Cardiotoxic drugs Herceptin and doxorubicin inhibit cardiac microvascular endothelial cell barrier formation resulting in increased drug permeability.

Authors:  Emma L Wilkinson; James E Sidaway; Michael J Cross
Journal:  Biol Open       Date:  2016-10-15       Impact factor: 2.422

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.